Vor Biopharma Q4 profit tops estimates on warrant fair value gain

Overview

• US biotech firm's Q4 net income beat analyst expectations, driven by warrant fair value changes

• Company completed $75 mln private placement, boosting pro-forma cash to $530.2 mln

• Q4 R&D expenses fell on lower headcount, G&A expenses rose on higher compensation and services

Outlook

• Vor Bio anticipates topline data from myasthenia gravis trial in 1H 2027

• Company expects pro-forma cash balance to fund operations into early 2029

• Vor Bio advancing telitacicept for potential regulatory approvals in US, Europe, Japan

Result Drivers

• WARRANT FAIR VALUE - Net income increase in Q4 was primarily due to gain on change in fair value of outstanding liability-classified warrants

• R&D SPENDING SHIFT - Q4 R&D expenses decreased due to lower headcount and reduced spend on previous programs, partially offset by increased spend on telitacicept programs

• G&A COST INCREASE - Q4 G&A expenses rose due to higher stock-based compensation, personnel costs and professional service costs

Company press release: ID:nGNX3Yy11h

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Vor Biopharma Inc is $43.00, about 197% above its March 27 closing price of $14.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.